Archive for the 'Epithelioid' Category
Epitheliod mesothelioma makes up between 50% and 70% of all diagnosed cases of mesothelioma; it also tends to have the best prognosis.
April 30th, 2008. The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma
Conclusions: In malignant pleural mesothelioma, the presence of occult disease in resection margins and lymph nodes can be identified by immunohistochemistry and significantly influences the prognosis. Cervical mediastinoscopy is useful in all patients considered for radical resection, but all specimens should be processed with immunohistochemical staining.
Posted in Biphasic or Mixed, Determining Efficacy, Diagnosis & Differentiation, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Immunohistochemistry or IHC, Pleural, Sarcomatoid, Staging, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 16th, 2008. Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma
The analysis of SMRP levels in these patients suggests that it may be a useful marker for monitoring the response to treatment. In fact, it was observed that SMRP increases in patients who did not respond to therapy, it tends to remain stable when therapies results into a clinical stabilization, while it decreases after surgical procedure and in case of clinical improvement.
April 9th, 2008. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma
In MPM, EGFR seems to play a role in a limited subset of patients. To identify possible candidates for EGFR tyrosine kinase in inhibitor therapy, the information on the EGFR gene status may be valuable.
Posted in Diagnosis & Differentiation, EGFR, Epithelioid, Full Archive, Immunohistochemistry or IHC, Kinase Inhibitors, New & Novel, Sarcomatoid, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 4th, 2008. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status
Conclusion: FACS analysis is more sensitive for evaluating mesothelin expression than immunohistochemistry of cut specimens. Irrespective of the expression of EGFR on FACS analysis, no EGFR mutation was detected. These three cell lines may be useful for studying cellular, molecular and genetic aspects of mesothelioma.
March 25th, 2008. Malignant pleural mesothelioma: Computed tomography and correlation with histology
Conclusions: Ipsilateral volume loss is most frequently associated with sarcomatous or mixed mesothelioma. The remaining imaging findings are not helpful in predicting the histological subtype of malignant mesothelioma.
Posted in Biphasic or Mixed, CT or CAT scan, Diagnosis & Differentiation, Epithelioid, Full Archive, Pleural, Pleural Effusion, Sarcomatoid, Symptoms & Symptom Management, Type of Assessment:, Type of Mesothelioma: | No Comments »
March 6th, 2008. Application of Immunohistochemistry to the Diagnosis of Malignant Mesothelioma
Conclusions: Various antibody panels have been recommended for the diagnosis of MM, with no overall consensus about how many and which markers should be used. A recent study with Bayesian statistics has demonstrated that the use of many markers does not provide higher diagnostic accuracy than the use of selected single antibodies or various combinations of only 2 markers. There is a need for the development of evidence-based or consensus-based guidelines for the diagnosis of MM in different differential diagnosis situations.
March 6th, 2008. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
We have further exploited the internalizing function of these scFvs to achieve targeted intracellular drug delivery to mesothelioma cells. We showed that scFv-targeted immunoliposomes were efficiently and specifically taken up by both epithelioid and sarcomatous mesothelioma cells, but not control cells, and immunoliposomes encapsulating the small-molecule drug topotecan caused targeted killing of both types of mesothelioma cells in vitro.
March 5th, 2008. Use of immunocytochemical assays in the study of exudates from serous cavities in the practical work of a laboratory
In 31 cases, adenogenic carcinoma metastases to the serous cavities were typified by an immunopositive reaction to CEA, Ber-EP4, EMA, and cytokeratins and a negative reaction to calretinin, mesothelin, and thrombomodulin. There was occasionally a positive reaction to CD-15 and vimentin.
February 29th, 2008. New diagnostic markers for malignant pleural mesothelioma
Despite a good sensitivity, osteopontin has a low specificity for mesothelioma diagnosis. However, there is not enough data yet to propose guidelines on the use of these markers in a day to day practice.
February 28th, 2008. Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes
In summary, MPM may present as mediastinal lymphadenopathy with metastases or it may be a concurrent neoplasm with other malignancies or shows an unusual immunohistochemical staining pattern. Caution should be used when diagnosing mesothelial cell inclusions in MLNs.
February 28th, 2008. Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors
Conclusion: MPM is an increasing disaster in Egypt which is underestimated and neglected. A panel of immunohistochemical markers should be used for proper evaluation. p27 has proven to be a potential biologic prognostic marker for mesothelioma and more studies as regard its significance are recommended on a larger number.
February 19th, 2008. Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital
Conclusions: In the cases studied, an integrated multidisciplinary approach was used, and a highly complex hospital infrastructure was available for the diagnosis and treatment of MPM, as recommended in the literature. However, the mean survival was only 11 months, reflecting the aggressiveness of the disease.
Posted in Biphasic or Mixed, Chemotherapy, Diagnosis & Differentiation, Epithelioid, Full Archive, General, Pleural, Pleural Biopsy, Pneumonectomy, Radiation, Sarcomatoid, Surgery, thoracoscopy, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
February 11th, 2008. Expression of mesothelin as a potential diagnostic marker in mesothelioma
None of the sarcomatoid mesotheliomas exhibited positivity for this marker, nor was any reactivity seen in the spindle cell component of the biphasic mesotheliomas. These findings indicate that, in some instances, mesothelin immunostaining can assist in the diagnosis of mesothelioma.
January 29th, 2008. Xanthomatous Pleuritis Mimicking Mesothelioma
Our patient quickly recovered with steroid therapy and is without recurrence 18 months later. This case demonstrates the utility and nuances of medical thoracoscopy in a perplexing case of xanthomatous pleuritis.
January 3rd, 2008. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells
In addition, a splice variant transcript of mesothelin (variant 3) was detected in these MPM cell lines, in accordance with the release of a secreted part of the protein. Our results indicate that both mechanisms could be implicated in soluble mesothelin production by epithelioid mesothelioma cells.
December 29th, 2007. Podoplanin is a Better Immunohistochemical Marker for Sarcomatoid Mesothelioma Than Calretinin
Overall sensitivities and pecificities were 84% and 99% for antipodoplanin, and 86% and 96% for D2-40. These findings suggest that cytoplasmic podoplanin expression may be useful in the diagnosis of sarcomatoid mesothelioma, although it should be used with caution on biopsy material.
December 25th, 2007. Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery
Conclusion: Our results suggest that surgery is indicated in treating localised MPM even in T4 (diffuse chest wall involvement) tumours but pleuropneumonectomy is not necessary. These tumours seem to have a different biological behaviour compared to diffuse MPM but further research, including identification of possibly different biological markers is necessary.
Posted in Biphasic or Mixed, Epithelioid, Full Archive, Pleural, Pleurectomy/decortication, Pneumonectomy, Sarcomatoid, Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 19th, 2007. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma
Conclusions: PET-CT seems to be a valuable tool in staging of MPM and leads to discordant findings in almost every second patient compared to CT alone. In many cases these differences are clinically relevant and have therapeutic consequences.
November 17th, 2007. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810)
Conclusions: Cisplatin–gemcitabine combination chemotherapy has modest activity with an acceptable toxicity profile, as first line treatment for patients with malignant mesothelioma.
|
|  |
